Artelo Biosciences (ARTL) Competitors $1.16 -0.04 (-3.33%) Closing price 02/21/2025 03:56 PM EasternExtended Trading$1.15 -0.01 (-0.52%) As of 02/21/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends ARTL vs. BMRA, EGRX, HCWB, CING, MTVA, CRVO, PHIO, NERV, TRIB, and CLRBShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Biomerica (BMRA), Eagle Pharmaceuticals (EGRX), HCW Biologics (HCWB), Cingulate (CING), MetaVia (MTVA), CervoMed (CRVO), Phio Pharmaceuticals (PHIO), Minerva Neurosciences (NERV), Trinity Biotech (TRIB), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Biomerica Eagle Pharmaceuticals HCW Biologics Cingulate MetaVia CervoMed Phio Pharmaceuticals Minerva Neurosciences Trinity Biotech Cellectar Biosciences Biomerica (NASDAQ:BMRA) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk. Which has better valuation and earnings, BMRA or ARTL? Biomerica has higher revenue and earnings than Artelo Biosciences. Biomerica is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.41M2.83-$5.98M-$0.34-2.46Artelo BiosciencesN/AN/A-$9.29M-$2.87-0.40 Do analysts rate BMRA or ARTL? Artelo Biosciences has a consensus target price of $5.50, indicating a potential upside of 374.14%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Does the media prefer BMRA or ARTL? In the previous week, Biomerica and Biomerica both had 1 articles in the media. Biomerica's average media sentiment score of 0.00 equaled Artelo Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomerica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in BMRA or ARTL? Biomerica received 91 more outperform votes than Artelo Biosciences when rated by MarketBeat users. However, 76.67% of users gave Artelo Biosciences an outperform vote while only 67.82% of users gave Biomerica an outperform vote. CompanyUnderperformOutperformBiomericaOutperform Votes13767.82% Underperform Votes6532.18% Artelo BiosciencesOutperform Votes4676.67% Underperform Votes1423.33% Which has more risk & volatility, BMRA or ARTL? Biomerica has a beta of -0.98, suggesting that its stock price is 198% less volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Is BMRA or ARTL more profitable? Artelo Biosciences has a net margin of 0.00% compared to Biomerica's net margin of -100.52%. Biomerica's return on equity of -90.19% beat Artelo Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-100.52% -90.19% -64.54% Artelo Biosciences N/A -104.59%-94.06% Do institutionals and insiders hold more shares of BMRA or ARTL? 22.3% of Biomerica shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 15.0% of Biomerica shares are owned by company insiders. Comparatively, 0.8% of Artelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryBiomerica and Artelo Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.87M$7.06B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.405.7326.0419.11Price / SalesN/A306.03447.4676.36Price / CashN/A65.6738.0134.83Price / Book0.286.717.644.62Net Income-$9.29M$138.33M$3.18B$245.85M7 Day Performance-2.52%-2.63%-2.00%-2.61%1 Month Performance-3.33%-2.33%-0.44%-2.14%1 Year Performance-30.54%-5.33%16.44%12.98% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences3.1848 of 5 stars$1.16-3.3%$5.50+374.1%-27.5%$3.87MN/A-0.405News CoverageBMRABiomerica0.4744 of 5 stars$0.83+6.7%N/A-22.6%$15.22M$5.41M-2.4460Gap UpEGRXEagle PharmaceuticalsN/A$1.17-0.8%N/A-76.1%$15.20M$316.61M0.00100HCWBHCW Biologics0.2621 of 5 stars$0.40-2.3%N/A-65.5%$15.13M$3.50M-0.4040CINGCingulate2.8593 of 5 stars$4.51+3.9%$16.00+254.8%+300.5%$14.49MN/A0.0020MTVAMetaVia1.6199 of 5 stars$1.67+1.5%$12.00+616.8%N/A$14.43MN/A0.0010Gap UpCRVOCervoMed3.6014 of 5 stars$2.33+6.4%$40.86+1,653.5%-84.3%$14.38M$7.14M0.004Analyst UpgradeNews CoveragePHIOPhio Pharmaceuticals3.3657 of 5 starsN/A$36.00+∞-75.3%$13.98MN/A0.0010Analyst ForecastAnalyst RevisionNews CoverageNERVMinerva Neurosciences3.2159 of 5 stars$1.97-3.9%$5.00+153.8%-79.3%$13.77MN/A-4.489Analyst ForecastNews CoverageTRIBTrinity Biotech0.4003 of 5 stars$0.76flatN/AN/A$13.72M$56.83M-0.34480CLRBCellectar Biosciences1.9774 of 5 stars$0.29+3.5%$17.67+5,975.2%-90.4%$13.40MN/A-0.1710Analyst Forecast Related Companies and Tools Related Companies Biomerica Alternatives Eagle Pharmaceuticals Alternatives HCW Biologics Alternatives Cingulate Alternatives MetaVia Alternatives CervoMed Alternatives Phio Pharmaceuticals Alternatives Minerva Neurosciences Alternatives Trinity Biotech Alternatives Cellectar Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARTL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
